Neurocrine Biosciences (NBIX) reported $687.5 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 16.5%. EPS of $1.06 for the same period compares to $0.63 a year ago.
The reported revenue represents a surprise of +5.72% over the Zacks Consensus Estimate of $650.3 million. With the consensus EPS estimate being $0.98, the EPS surprise was +8.16%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net: $682 million versus $635.87 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +16.8% change.
- Revenues- Collaboration revenue: $5.5 million versus the 10-analyst average estimate of $6.04 million. The reported number represents a year-over-year change of -14.1%.
- Revenues- Product sales, net- INGREZZA: $624.4 million versus the nine-analyst average estimate of $620.8 million. The reported number represents a year-over-year change of +7.8%.
- Revenues- Product sales, net- CRENESSITY: $53.2 million compared to the $19.82 million average estimate based on eight analysts.
- Revenues- Product sales, net- Other: $4.4 million versus $4 million estimated by two analysts on average.
- Revenues- Collaboration revenue- Royalty: $5.1 million versus $5.35 million estimated by two analysts on average.
View all Key Company Metrics for Neurocrine here>>>
Shares of Neurocrine have returned +4.8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
